Kula Investments’s Corcept Therapeutics CORT Stock Holding History

Kula Investments’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-35,174	Closed	-$714K	–	647
2022 Q4	$714K	Buy	+35,174	New	+$882K	0.21%	119

Other funds holding CORT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Kula Investments's CORT Position: Q1 2023 in Review

Kula Investments sold out of Corcept Therapeutics (CORT) in Q1 2023, closing a stake of 35,174 shares — an estimated $714K sold.

Kula Investments first reported a position in CORT in Q4 2022 and held it in 1 quarter. The position peaked at $714K in Q4 2022. 232 funds tracked by Wall St. Rank hold CORT as of Q1 2023.

Kula Investments reported no remaining Corcept Therapeutics position as of Q1 2023 after selling out during the quarter.
Kula Investments sold 35,174 Corcept Therapeutics shares in Q1 2023, an estimated $714K.
Kula Investments first reported a position in Corcept Therapeutics in Q4 2022 and held it in 1 quarter.
Kula Investments's Corcept Therapeutics position peaked at $714K in Q4 2022.
232 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2023.

Based on Kula Investments's 13F filing for Q1 2023, filed 15 May 2023.